- Home
- IMPP vs CRBU Comparison
IMPP vs CRBU Comparison
Compare IMPP & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMPP
- CRBU
- Stock Information
- Founded
- IMPP 1981
- CRBU 2011
- Country
- IMPP Greece
- CRBU United States
- Employees
- IMPP N/A
- CRBU N/A
- Industry
- IMPP Marine Transportation
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- IMPP Consumer Discretionary
- CRBU Health Care
- Exchange
- IMPP Nasdaq
- CRBU Nasdaq
- Market Cap
- IMPP 99.2M
- CRBU 93.0M
- IPO Year
- IMPP N/A
- CRBU 2021
- Fundamental
- Price
- IMPP $2.32
- CRBU $0.79
- Analyst Decision
- IMPP
- CRBU Strong Buy
- Analyst Count
- IMPP 0
- CRBU 5
- Target Price
- IMPP N/A
- CRBU $11.80
- AVG Volume (30 Days)
- IMPP 136.9K
- CRBU 976.1K
- Earning Date
- IMPP 05-15-2025
- CRBU 05-06-2025
- Dividend Yield
- IMPP N/A
- CRBU N/A
- EPS Growth
- IMPP N/A
- CRBU N/A
- EPS
- IMPP 1.40
- CRBU N/A
- Revenue
- IMPP $147,479,980.00
- CRBU $9,994,000.00
- Revenue This Year
- IMPP $3.05
- CRBU N/A
- Revenue Next Year
- IMPP $47.92
- CRBU $163.34
- P/E Ratio
- IMPP $1.65
- CRBU N/A
- Revenue Growth
- IMPP N/A
- CRBU N/A
- 52 Week Low
- IMPP $2.23
- CRBU $0.72
- 52 Week High
- IMPP $4.59
- CRBU $4.85
- Technical
- Relative Strength Index (RSI)
- IMPP 31.99
- CRBU 30.32
- Support Level
- IMPP $2.35
- CRBU $0.72
- Resistance Level
- IMPP $2.50
- CRBU $1.01
- Average True Range (ATR)
- IMPP 0.08
- CRBU 0.09
- MACD
- IMPP -0.00
- CRBU -0.00
- Stochastic Oscillator
- IMPP 11.11
- CRBU 20.06
About IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil and jet fuel, as well as edible oils and chemicals.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.